Sun Pharma Brokerage Review: Citi, HSBC Maintain Buy; BofA Retains Underperform
NDTV

Ilumya's US sales challenges, higher R&D; spending, and the growth prospects
of Leqselvi and Unloxcyt remain key factors shaping brokerage views on Sun
Pharma.
NDTV

Ilumya's US sales challenges, higher R&D; spending, and the growth prospects
of Leqselvi and Unloxcyt remain key factors shaping brokerage views on Sun
Pharma.
Several outlets reported this. AI can compare where they agree and differ.
MarketsEconomic Times
Sun Pharma stock is experiencing current market performance updates.
MarketsEconomic Times
Emcure Pharma shares hit a 10% upper circuit after strong Q2 FY27 results prompted the company to raise its full-year growth guidance. Brokerages turned more positive, citing robust international business, improving domestic growth and a strong product pipeline.
MarketsEconomic Times
Global brokerages HSBC, Citigroup, and Jefferies turned bullish on Indian equities following a market rebound and improving earnings.
EconomyCNBC-TV18
Of the 41 analysts who have coverage on the Britannia Industries stock, 32 have "buy" recommendations, seven have "hold" ratings and two have "sell" ratings.
MarketsNDTV
Brokerages maintained positive ratings on Grasim while cutting target prices due to paints business and chemical pressures.
EconomyNDTV
Escorts Kubota faces near-term challenges from weaker tractor demand and rising commodity costs. However, Kotak sees opportunities in market-share gains, construction equipment, and business diversification.
MarketsCNBC-TV18
Biocon shares gained after the US FDA approved its cancer drug biosimilar, with a US launch expected in 2028.